Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | LPL | P06858 | 3/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19790075 | 0.71 | P2RX7 (0.33) | P2RX7MAPK1 | |
| SCHEMBL22640808 | 0.70 | USP30 (0.37) | P2RX7MAPK1FFAR1 | |
| SCHEMBL7890712 | 0.69 | P2RX7 (0.47) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL21979659 | 0.68 | P2RX7 (0.42) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL10231629 | 0.68 | P2RX7 (0.42) | P2RX7MAPK1LPLLIPGFFAR1 | |
| SCHEMBL22212831 | 0.67 | P2RX7 (0.53) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL10224311 | 0.67 | P2RX7 (0.53) | P2RX7MAPK1 | |
| SCHEMBL14330689 | 0.66 | P2RX7 (0.57) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL20085187 | 0.66 | P2RX7 (0.40) | P2RX7MAPK1 | |
| SCHEMBL18761823 | 0.66 | P2RX7 (0.43) | P2RX7MAPK1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059000-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INFINITY PHARMACEUTICALS, INC. | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059000-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | MAP3K13, AKT3, PIK3CA | P2RX7 1658/4885MAPK1 128/4885LPL 1861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.